Assay Prediction

Pathology

Clinical Features

Tissue of Origin

Veridex

Histology

IHC

Age/Sex

Sites of Metastasis

Intrathoracic Location (Y/N)

Response to Treatment

Survival (mo)

NSCLC

NSCLC

PD adenocarcinoma

TTF1+, CEA+, Pan-CK+, S100-

45/F

bone, soft tissue

N

PD

8

NSCLC

NSCLC

PD carcinoma

CK AE1/AE3+, HMB45-, CK20-, CK7+, AFP-, BhCG-

54/F

lymph nodes

Y

CR

65

NSCLC

NSCLC

PD carcinoma

CK7+, CEA+, B14/18+, S100-, PSA-, PSAP-, HMB45-

60/M

kidney, spleen

N

PD

9

NSCLC

NSCLC

PD carcinoma

CK+, EMA+, CD30-, LCA-

74/M

liver, lung, lymph nodes

Y

PR

24

NSCLC

NSCLC

PD carcinoma

AE1/AE3+, chromogranin-, synaptophysis-, S100-, HMB45-, LCA-

64/M

liver, lung, lymph nodes, kidney

Y

PR

8

NSCLC

NSCLC

PD carcinoma

None

68/M

pancreas, lymph nodes, lung

Y

SD

14

NSCLC

Colon

Squamous

None

59/M

lymph nodes, soft tissue

Y

PD

6

NSCLC

Other

Squamous

None

43/M

liver, lung, bone, lymph nodes

Y

PR

11

NSCLC

Other

PD adenocarcinoma

None

72/F

lung

Y

PD

30

NSCLC

Pancreas

PD adenocarcinoma

None

65/M

abdomen, lung, bone

Y

UE

<1

NSCLC

Pancreas

PD adenocarcinoma

None

54/M

lymph nodes

Y

PR

33+

Ovarian

NSCLC

PD adenocarcinoma

CK+, CEA+, CK20+, ER-, PR-, HMB45-, S100-, CK7-, Her2/neu-

51/F

lung, liver, lymph nodes

Y

PD

5

Colorectal

NSCLC

PD adenocarcinoma

CK20+, CK+, PLAP-, PSA/PSAP-, melanin A-

71/M

abdomen, soft tissue

N

SD

21

Bladder

NSCLC

Squamous

None

60/M

Soft tissue

N

UE

32

Non-diagnostic

NSCLC

Squamous

TTF1-

55/M

lung, soft tissue

Y

SD

9

Table 3: Clinicopathologic Characteristics of Patients with NSCLC Predictions (n = 15).